<DOC>
	<DOCNO>NCT02017197</DOCNO>
	<brief_summary>The purpose study ass whether switch brand generic warfarin different generic warfarin tablet may cause fluctuation result coagulation test ( International Normalized Rate , acronym INR ) patient , thus predispose unnecessary risk .</brief_summary>
	<brief_title>Therapeutic Equivalence Between Branded Generic WARFArin Tablets Brazil</brief_title>
	<detailed_description>[ Changes protocol make stage statistical analysis plan , data analysis also unblinding . ] 1 . Objective 1.1 Main Objective We aim determine , mean INR difference formulation , whether therapeutic equivalency brand warfarin sodium ( Marevan® ) generic formulation atrial fibrillation patient Brazil . 1.2 Specific Objective In order achieve objective , aim ass warfarin formulation : - Delta INR [ new primary outcome ] ; - mean INR [ mean prothrombin time analyze since convey information mean INR ] ; - mean dosage need anticoagulation [ new outcome ] ; - clinical event ( frequency thromboembolic event , bleeding , death adverse event ) ; - time therapeutic range ; - compliance treatment . 2 . Hypothesis Our hypothesis delta INR patient use generic tablet warfarin sodium differ 0.49 ( two-sided ) mean INR obtain use branded formulation , thereby demonstrate therapeutic equivalence . We also assess outcome ass therapeutic equivalence generic formulation . 3 . Type Study This study crossover randomize control equivalence trial . It comprise four phase , one one-month long , first one run-in period . Patients use different warfarin sodium tablet formulation one phase 2 , 3 4 : either brand Marevan® ( União Química/Farmoquímica , Brasil ) , two generic drug , ( manufacture União Química Farmacêutica Nacional S/A Laboratório Teuto Brasileiro S/A , Brasil ) purchase Brazilian drugstore ( directly manufacturer ) . Every patient use one three formulation previously determine sequence ( A , B , C , D , E F ) assign randomization . Since patient include study already use warfarin ethically acceptable interrupt treatment , plan run-in period equivalent seven warfarin half-lives , long enough washout previous warfarin treatment . Then , first phase , patient start treatment warfarin formulation use second phase thus avoid carry-over effect . This period also use select patient compliant treatment , accept run-in least one three ( include baseline ) INR result within 2.0 3.0 difference INR result 3th 4th week ≤ ±0.8 . 4 . Methods An independent investigator ( initial TFCP ) use computer random number generator allocate patient one six sequence treatment [ update : opt apply randomization number , opaque , seal envelope order facilitate allocation concealment ] . The principal investigator ( initial CGF ) separate , repack dispense drug patient opaque drug container identical appearance [ update : step repacking drug opaque container make two investigator external study , BR MFST , instead principal investigator ] . This process base initial patient alphanumeric code , maintain allocation concealment since TFCP responsible assign repacked drug patient initial alphanumeric code correlate formulation warfarin utilized . TFCP also accountable conceal allocation statistical analysis end study [ update : BR MFST create cod maintain concealment ] . Due feature drug container , physician principal investigator ( assess patient collect outcome ) blind . Patients may blind depend appearance manufacture tablet , main outcome laboratory result ( INR ) . 5 . Sample Size Forty-eight patient ( eight group ) minimum necessary number individual detect clinically significant fluctuation 0.49 mean INR , 90 % power 5 % level significance , one present . This sample size estimate consider Pocock 's statistical method quantitative outcome achieve mean INR standard deviation brand warfarin 2.45 0.29 respectively [ update : later consider conservative standard deviation 0.34 , result sample size 11 patient per group ] . To compensate possible withdrawal exclusion patient plan recruit 60 patient . 6 . Statistical Analysis For INR , PT TTR outcomes pair t-test used two-sided 5 % level significance . These analysis per protocol , i.e. , data patient follow-up start treatment substance drug interact either moderate major way contraindicate used warfarin ( Annex I ) exclude [ update : multiple t-tests would adequate nominal significance level would reflect actual alfa , thus decide apply multilevel mixed-effects linear regression . We new definition per protocol analyses. ] . Binary outcome ( thromboembolic bleed event ) analyse Mcnemar test 5 % level significance use intention treat i.e . consider miss data adverse outcome . In case sensibility analysis conduct [ update : decide present event record trial without hypothesis test due cross-over design limitation low power outcome ] . Exploratory analysis subgroup patient intend . 7 . Annex I ( obtain online database Micromedex ® 2.0 September 13 , 2013 ) - abciximab - acarbose - acemetacin - acenocoumarol - acetaminophen - agrimony - alclofenac - alefacept - allopurinol - aloe - aminoglutethimide - amiodarone - amitriptyline - amobarbital sodium - amoxapine - amoxicillin - ampicillin trihydrate - amprenavir - angelica - anise - antithyroid agent - apazone - apixaban - aprepitant - aprobarbital - argatroban - armodafinil - arnica - asafetida - aspirin - astragalus - atazanavir - atenolol - atovaquone - avocado - azathioprine - azithromycin - bee pollen - benoxaprofen - benzbromarone - betamethasone - bicalutamide - bilberry - bismuth subsalicylate - bivalirudin - black cohosh extract - black currant - black haw - black tea - bladderwrack - boceprevir - bogbean - boldo - borage - bosentan - bromelain - bromfenac - buchu - bufexamac - butabarbital - butalbital - capecitabine - capsaicin - carbamazepine - carbenicillin disodium - carboplatin - carprofen - cassia - cat 's claw - cefadroxil - cefamandole - cefazolin sodium - cefdinir - cefepime - cefixime - cefoperazone - cefotaxime - cefotetan - cefpodoxime - ceftazidime - ceftibuten - ceftizoxime - ceftriaxone - celecoxib - celery - cephalexin - cephalothin sodium - cephapirin - chamomile - chaparral - chitosan - chloral hydrate - chloramphenicol - chlordiazepoxide - chlorotrianisene - chlorpromazine hydrochloride - cholestyramine - chondroitin - cimetidine - cinchona - ciprofloxacin - cisapride monohydrate - cisplatin - citalopram - clarithromycin - clofibrate - clomipramine hydrochloride - clopidogrel - clove - clove oil - cloxacillin benzathine - coenzyme Q10 - colesevelam - contraceptive , combination - cortisone - cranberry juice - curcumin - cyclophosphamide - cyclosporine , modify - dabigatran - dabrafenib - dalteparin - danaparoid - danazol - dandelion - dapsone - darunavir - deferasirox - delavirdine - demeclocycline - desipramine - desvenlafaxine - devil 's claw - dexamethasone - dexlansoprazole - dexmethylphenidate - diazoxide - diclofenac - dicloxacillin - diethylstilbestrol - diflunisal - dipyridamole - dipyrone - disopyramide - disulfiram - dong quai - dothiepin - doxepin - doxorubicin - doxycycline calcium - dronedarone - droxicam - duloxetine - enoxacin - enoxaparin - enteral nutrition - enzalutamide - eptifibatide - erlotinib - erythromycin acistrate - escitalopram - esomeprazole - eterobarb - ethacrynic acid - ethanol - ethchlorvynol - ethotoin - etodolac - etoposide - etravirine - etretinate - evening primrose oil - exenatide - ezetimibe - felbamate - fenbufen - fenofibrate - fenofibric acid - fenoprofen - fenugreek - feverfew - fish oil - floctafenine - flosequinan - fluconazole - fludrocortisone acetate - flufenamic acid - fluorouracil - fluoxetine - fluoxymesterone - flurbiprofen - flutamide - fluvastatin - fluvoxamine - fosamprenavir - fosaprepitant - garlic - gatifloxacin - gefitinib - gemcitabine - gemfibrozil - gemifloxacin - ginger - ginkgo - ginseng , siberian - glimepiride - glipizide - glucagon - glucosamine - glutethimide - glyburide - goldenseal - green tea - griseofulvin - guggul - halothane - heparin calcium - heptabarbital - hexobarbital sodium - high protein food - horse chestnut - horseradish - hydrocortisone - ibritumomab - ibuprofen - ifosfamide - imatinib - imipramine hydrochloride - indomethacin - indoprofen - infliximab - influenza virus vaccine - ipriflavone - isoniazid - isoxicam - itraconazole - ivacaftor - ivermectin - kava - ketoconazole - ketoprofen - ketorolac tromethamine - lactulose - lansoprazole - leflunomide - lepirudin - levamisole - levofloxacin - licorice - lopinavir - lornoxicam - lovastatin - lycium - marijuana - meadowsweet - mechlorethamine - meclofenamate - mefenamic acid - melatonin - meloxicam - menthol - mephobarbital - mercaptopurine - mesalamine - mesna - methandrostenolone - methicillin - methotrexate - methyl salicylate - methylphenidate - methylprednisolone acetate - methyltestosterone - metronidazole - miconazole - mifepristone - milnacipran - minocycline hydrochloride - mistletoe - mitotane - moricizine hydrochloride - motherwort - moxalactam - moxifloxacin - nabumetone - nafcillin - nalidixic acid - nandrolone - naproxen - nelfinavir - neomycin - nettle extract - nevirapine - niacin - nilutamide - nimesulide - norfloxacin - nortriptyline hydrochloride - noscapine - ofloxacin - omega-3-acid ethyl ester - omeprazole - onion oil - orlistat - oseltamivir - oxacillin - oxandrolone - oxaprozin - oxymetholone - oxyphenbutazone - oxytetracycline - pantoprazole - papaya - paramethasone - paroxetine - parsley - passionflower - pau d'arco - penicillin G - penicillin V benzathine - pentosan polysulfate sodium - pentoxifylline - phenindione - phenobarbital - phenprocoumon - phenylbutazone - phenytoin - phytonadione - piperacillin - piracetam - pirazolac - piroxicam - pirprofen - policosanol - pomegranate - poplar - posaconazole - prasugrel - prednisolone - prednisone - prickly ash - primidone - procarbazine - proguanil - propafenone hydrochloride - propoxyphene - propranolol - propyphenazone - proquazone - protriptyline - pumpkin seed - quassia - quetiapine - quinestrol - quinidine - quinine - rabeprazole sodium - raloxifene - ranitidine - red clover - rifabutin - rifampin - rifapentine - rifaximin - rilonacept - ritonavir - rivaroxaban - rofecoxib - romidepsin - ropinirole - rosuvastatin - roxithromycin - salicylates - saquinavir - sarsaparilla - saw palmetto extract - secobarbital - senega - sertraline - simvastatin - sitaxsentan - skullcap - sorafenib - soybean - spironolactone - st john 's wort - stanozolol - sucralfate - sulfamethoxazole - sulfasalazine - sulfinpyrazone - sulfisoxazole - sulindac - sulofenur - suprofen - sweet woodruff - tamarind - tamoxifen - tan shen - teduglutide - telaprevir - telithromycin - tenidap sodium - tenoxicam - terbinafine - teriflunomide - testosterone - tetracycline - thyroid hormone - tiaprofenic acid - tibolone - ticarcillin - ticlopidine - tigecycline - tinidazole - tinzaparin - tirofiban - tocilizumab - tolmetin - tolterodine tartrate - tonka - toremifene citrate - torsemide - tramadol - trastuzumab - treprostinil - triamcinolone acetonide - trimipramine - valdecoxib - valproic acid - vancomycin - vemurafenib - venlafaxine - vilazodone - vincristine - vindesine - vitamin A - vitamin E - vitamin K - voriconazole - vorinostat - wild lettuce - willow - wintergreen - yarrow - zafirlukast - zileuton - zomepirac sodium - zotepine</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>diagnosis nonvalvular atrial fibrillation atrial flutter electrocardiogram echocardiography ; CHA2DS2VASc score equal great 1 ; already use warfarin least 2 month ; runin , least one three ( include baseline ) INR result within 2.0 3.0 difference INR result 3th 4th week ≤ ±0.8 signing Informed Consent Form . patient serious contraindication use anticoagulant ( significant bleeding , know sensitivity warfarin ) ; woman childbearing age , pregnant breastfeeding ; patient thrombocytopenia ; patient hepatic renal impairment ; patient history bleed episode due congenital deficiency coagulation factor ; patient enrol another trial ; patient initiate treatment drug major interaction contraindicate use concomitantly warfarin , accord list ( Annex I ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Therapeutic Equivalency</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Drugs , Generic</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Anticoagulants [ Pharmacological Action ]</keyword>
	<keyword>Coumarins</keyword>
</DOC>